---
document_datetime: 2023-09-21 20:17:53
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/bortezomib-fresenius-kabi-epar-all-authorised-presentations_en.pdf
document_name: bortezomib-fresenius-kabi-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8146727
conversion_datetime: 2025-12-31 05:09:28.38487
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) Numbers   | (Invented) name           | Strength   | Pharmaceutical Form               | Route of Administration           | Immediate Packaging   | Pack size   |
|-------------------|---------------------------|------------|-----------------------------------|-----------------------------------|-----------------------|-------------|
| EU/1/19/1397/001  | Bortezomib Fresenius Kabi | 3.5 mg     | Powder for solution for injection | Intravenous use, Subcutaneous use | vial (glass)          | 1 vial      |
| EU/1/19/1397/002  | Bortezomib Fresenius Kabi | 1 mg       | Powder for solution for injection | Intravenous use                   | vial (glass)          | 1 vial      |
| EU/1/19/1397/003  | Bortezomib Fresenius Kabi | 2.5 mg     | Powder for solution for injection | Intravenous use, Subcutaneous use | vial (glass)          | 1 vial      |